Noxopharm to Commence Veyonda^®’s Clinical Trial in COVID-19 Patients in Europe

• June 22, 2020 04:03 PM AEST
• Team Kalkine

Australian clinical stage drug developer, Noxopharm Limited (ASX:NOX) notified in its latest update the commencement of NOXCOVID clinical trial program in Europe, focusing on safety and proof-of principle endpoints of Veyonda® as a potential tr...

• June 03, 2020 11:42 AM AEST
• Team Kalkine

Summary Noxopharm presented two sets of clinical data concerning the development of Veyonda® as a treatment for end-stage prostate cancer at ASCO 2020 Annual Meeting. Highly encouraging interim data from the Phase 1b/2a LuPIN clinical trial...

• May 25, 2020 01:02 PM AEST
• Team Kalkine

Marking a step forward, clinical-stage drug development company Noxopharm (ASX:NOX) has lodged a pre-IND (Investigational New Drug) submission with the U.S. Food and Drug Administration (FDA) for a Veyonda® clinical trial in COVID-19 (SARS-C...

• May 06, 2020 02:19 PM AEST
• Team Kalkine

Biotech company Noxopharm Limited (ASX:NOX) possesses an exciting new potential treatment for end-stage prostate cancer as suggested by the latest radiographic review of DARRT-1 clinical study, supporting the Company’s belief in the anti-cancer...

• April 30, 2020 03:42 PM AEST
• Team Kalkine

In a new development, clinical-stage oncology drug development player Noxopharm Limited (ASX:NOX) has confirmed that an isoflavonoid drug candidate has passed the proof-of-principle test for its brain cancer program in laboratory studies, paving the ...

• April 22, 2020 01:59 PM AEST
• Team Kalkine

Clinical-stage Australian oncology drug development player Noxopharm (ASX:NOX) has revealed that the active ingredient in Veyonda® - idronoxil, blocks the STING (Stimulator of Interferon Genes) signalling pathway associated with the type of cellu...

• April 06, 2020 01:49 PM AEST
• Team Kalkine

Australian oncology drug development company Noxopharm (ASX:NOX), along with the Hudson Institute of Medical Research in Melbourne, has identified anti-inflammatory properties of idronoxil, consistent with reducing a ‘cytokine storm’ whic...

• March 26, 2020 12:55 PM AEDT
• Team Kalkine

Australian clinical stage drug development company Noxopharm Limited (ASX:NOX) recently announced a significant milestone, that its potentially transformative anti-cancer drug candidate Veyonda® has been awarded first allowed patent application (...

• February 25, 2020 06:53 PM AEDT
• Team Kalkine

Latest LuPIN Trial Interim Results and an Alliance with Oncology Services Provider, GenesisCare Further Enhance Veyonda®’s Potential Commercial and Shareholder Value  Australian clinical-stage drug development company Noxopharm Limite...

• February 10, 2020 02:58 PM AEDT
• Team Kalkine

Noxopharm Limited (ASX:NOX), an Australian clinical stage biotechnology company with its focus on oncology, is known for developing a novel, potentially transformative and industry disruptive cancer drug treatment using its lead candidate, Veyonda&re...